O
BIO icon

OppenheimerFunds’s Bio-Rad Laboratories Class A BIO Stock Holding History

OppenheimerFunds’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		$15.5M Sell
50,819
-15,607
-23% -$4.21M 0.02% 597
2018
Q4 		$15.4M Sell
66,426
-12,843
-16% -$3.45M 0.02% 571
2018
Q3 		$24.8M Buy
79,269
+24,625
+45% +$7.64M 0.03% 529
2018
Q2 		$15.8M Buy
54,644
+10,833
+25% +$2.99M 0.02% 640
2018
Q1 		$11M Buy
43,811
+4,093
+10% +$1.04M 0.01% 681
2017
Q4 		$9.48M Buy
39,718
+837
+2% +$203K 0.01% 742
2017
Q3 		$8.64M Sell
38,881
-6,413
-14% -$1.44M 0.01% 761
2017
Q2 		$10.3M Buy
45,294
+13,304
+42% +$2.9M 0.01% 737
2017
Q1 		$6.38M Buy
31,990
+29,592
+1,234% +$5.7M 0.01% 818
2016
Q4 		$437K Buy
2,398
+418
+21% +$71.3K ﹤0.01% 1443
2016
Q3 		$324K Sell
1,980
-78
-4% -$11.8K ﹤0.01% 1462
2016
Q2 		$294K Sell
2,058
-32
-2% -$4.56K ﹤0.01% 1471
2016
Q1 		$286K Sell
2,090
-365
-15% -$47.9K ﹤0.01% 1470
2015
Q4 		$340K Buy
+2,455
New +$340K ﹤0.01% 1460

Other funds holding BIO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
ACM
Atlanta Capital Management Atlanta, Georgia $22.5B AUM 9.67% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
EIP
Easterly Investment Partners Beverly, Massachusetts $1.97B AUM 25.87% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return

OppenheimerFunds's BIO Position: Q1 2019 in Review

OppenheimerFunds reduced its Bio-Rad Laboratories Class A (BIO) stake by 23% in Q1 2019, selling an estimated $4.21M and leaving 50,819 shares worth $15.5M. The position accounts for 0.02% of the portfolio, ranked #597.

OppenheimerFunds first reported a position in BIO in Q4 2015 and has held it in 14 quarters since. The position peaked at $24.8M in Q3 2018. 347 funds tracked by Wall St. Rank hold BIO as of Q1 2019.

  • OppenheimerFunds held 50,819 shares of Bio-Rad Laboratories Class A worth $15.5M as of Q1 2019.
  • OppenheimerFunds sold 15,607 Bio-Rad Laboratories Class A shares in Q1 2019, an estimated $4.21M.
  • Bio-Rad Laboratories Class A made up 0.02% of OppenheimerFunds's portfolio in Q1 2019, its #597 holding.
  • OppenheimerFunds first reported a position in Bio-Rad Laboratories Class A in Q4 2015 and has held it in 14 quarters since.
  • OppenheimerFunds's Bio-Rad Laboratories Class A position peaked at $24.8M in Q3 2018.
  • 347 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q1 2019.

Based on OppenheimerFunds's 13F filing for Q1 2019, filed 13 May 2019.